Web of Biological Data Act of 2026
Introduced June 11, 2026 · Last action June 11, 2026
Plain English Summary
This bill requires the U.S. Department of Energy to create a centralized data hub that makes biological research datasets available to scientists and computational researchers, enabling them to use artificial intelligence and advanced computing methods. The bill aims to speed up biological discoveries by removing barriers to data access and sharing.
Who benefits
Researchers in academia, national laboratories, and private biotech companies (especially those specializing in AI-driven drug discovery, genomics, and synthetic biology); software and AI firms building computational biology tools; pharmaceutical and biotechnology companies seeking faster pathways to drug development; universities with biology and computational science programs; tech companies offering cloud computing and AI services for life sciences research
Who pays / loses
Taxpayers funding the Department of Energy's operational costs to build and maintain the centralized data system; competing private data platforms and bioinformatics services that charge for data access; institutions currently licensing proprietary biological datasets may face reduced revenue if data becomes freely available through the centralized hub
Funding & Lobbying Interests
Pharmaceutical and biotechnology companies invest heavily in AI-driven drug discovery and would benefit from streamlined data access; cloud computing providers (Amazon Web Services, Google Cloud, Microsoft Azure) have financial interest in hosting and processing centralized biological datasets; academic research institutions and national laboratories (which receive DOE funding) benefit from improved data infrastructure; artificial intelligence and machine learning software vendors targeting life sciences applications have direct financial stakes in expanded computational biology adoption
Political Impact
Affected Groups
Biomedical researchers and graduate students (millions across U.S. universities and national labs); pharmaceutical and biotechnology companies ranging from large incumbents (Johnson & Johnson, Pfizer, Roche) to smaller biotech startups; healthcare patients who may benefit from accelerated drug discovery; technology workers in computational biology roles; countries competing in biotech innovation (particularly relevant to U.S.-China competition in AI-driven life sciences)
Political Subtext
Proponents frame this as accelerating American biomedical innovation and creating a public good by democratizing access to research data. They cite the competitive advantage gained by AI-enhanced drug discovery. Critics may argue the bill creates government infrastructure that could be built more efficiently by private companies, or that centralizing sensitive biological data raises privacy and biosecurity concerns that are not addressed in the bill text. The non-partisan case for government-led data infrastructure has merit in cases of market failure (researchers cannot afford private access, fragmentation wastes resources), though the bill text does not analyze whether such market failures actually exist or quantify expected benefits.
Real-World Stakes
If passed, this establishes a new DOE-administered system that could significantly speed access to biological datasets for thousands of researchers. Similar centralized repositories (e.g., the National Center for Biotechnology Information's GenBank, the Human Cell Atlas) have demonstrably accelerated research by reducing duplication and enabling large-scale computational analysis. However, the bill does not specify data governance, security standards, or how the government will manage proprietary data contributions, intellectual property rights, or international data sharing—creating risk of implementation delays or disputes. Analogous models at the international level (European Open Science Cloud) have faced adoption delays due to unclear data ownership rules. The real-world impact depends entirely on implementation details not addressed in the bill's language.
Sponsor
Co-sponsors (3)
DSen. Padilla, Alex [D-CA]RSen. Rounds, Mike [R-SD]DSen. Kim, Andy [D-NJ]
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
Top contributing industries
Other$118,150
Finance$22,150
Construction$6,700
Transportation$5,000
Technology$2,675
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.